Clinical Trial Detail

NCT ID NCT01966003
Title Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Amgen
Indications

lung non-small cell carcinoma

Therapies

Bevacizumab

Bevacizumab-awwb

Carboplatin + Paclitaxel

Age Groups: adult

No variant requirements are available.